Generic Name and Formulations:
Bosutinib 100mg, 400mg, 500mg; tabs.
Indications for BOSULIF:
Newly-diagnosed chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.
Take with food. Swallow whole. Continue until disease progression or patient intolerance. Newly-diagnosed: 400mg once daily. Renal impairment (CrCl 30–50mL/min): initially 300mg daily; (CrCl <30mL/min): initially 200mg daily. With resistance/intolerance to prior therapy: 500mg once daily. Renal impairment (CrCl 30–50mL/min): initially 400mg daily; (CrCl <30mL/min): initially 300mg daily. Both: hepatic impairment: initially 200mg daily. Dose escalation or dose adjustments for toxicity: see full labeling.
<18yrs: not established.
Monitor and manage GI toxicity, fluid retention; withhold, reduce dose, or discontinue as necessary. Perform CBC weekly for first month, then monthly; hepatic enzyme tests monthly for first 3 months (more frequently if transaminase elevations occur); withhold, reduce dose, or discontinue as necessary. Monitor renal function at baseline and during therapy; consider adjusting dose if renal impairment occurs. Dialysis: not studied. Embryo-fetal toxicity. Pregnancy; exclude status prior to initiation. Females of reproductive potential should use effective contraception during and for ≥1 month after last dose. Nursing mothers: not recommended (during and for ≥1 month after last dose).
Tyrosine kinase inhibitor.
Potentiated by concomitant strong or moderate CYP3A inhibitors (eg, ketoconazole, aprepitant, grapefruit products); avoid. Antagonized by concomitant strong or moderate CYP3A inducers (eg, rifampin, St. John’s wort); avoid. Antagonized by proton pump inhibitors (eg, lansoprazole); consider short-acting antacids or H2 blockers instead; separate dosing by ≥2hrs.
Diarrhea, nausea, thrombocytopenia, rash, vomiting, abdominal pain, anemia, pyrexia, abnormal LFTs, fatigue, cough, headache, edema; fluid retention, hepatic or renal toxicity.
Hepatic (CYP3A4); 94% protein bound.
Fecal (primary), renal.
Tabs 100mg—120; 400mg, 500mg—30
Neurology Advisor Articles
- Higher Levels of Cholesterol May Protect Men From Parkinson Disease
- Ajovy Injection Approved for Migraine Prevention in Adults
- Chronic Pain May Be Contributor to Suicide
- FDA Approves Tiglutik for the Treatment of Amyotrophic Lateral Sclerosis
- Natalizumab Improves Cognitive Function in Multiple Sclerosis
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- New 15-Item Dyspnea-ALS-Score Assesses Dyspnea in ALS
- CDC: About One in Five U.S. Adults Have Chronic Pain
- Fingolimod Cuts Multiple Sclerosis Relapses in Pediatric Patients
- Gains in Insurance Coverage Seen for Lesbian, Gay, Bisexual Adults
- Brivaracetam Effective for Reducing Seizures in Patients with Epileptic Encephalopathies